chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 16.0
Sex: M
Vaccine: MNQ
Symptoms: Local reaction
Clinical narrative: Large local reaction on Left arm. Pt advised to ice and take ibuprofen as needed.
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthropathy, Chest X-ray normal, Cold sweat, Computerised tomogram head normal, Computerised tomogram neck
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Echocardiogram normal, Hyperhidrosis, Magnetic resonance imaging brain normal, Magnetic resonance imaging neck, Motion sickness
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Muscle disorder, Troponin I increased, Urinary incontinence, Vertigo, Vision blurred
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Chest X-ray normal, Computerised tomogram head normal, Dizziness, Electrocardiogram normal
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Magnetic resonance imaging brain normal, Myalgia, Nausea, Troponin increased, Urinary incontinence
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vertigo, Vomiting
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 53.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Unevaluable event
Clinical narrative: THIS IS A FOLLOW-UP VAERS REPORT TO INTIAL VAERS REPORT 942879-1 filed on 13 JAN 2021.   SEE FOLLOW-UP VAERS SUPPLEMENT
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Fatigue, Headache, Hyperhidrosis, Myalgia
Clinical narrative: pain and swelling in myarmpit; hungry; developed fever, went up to 103.5, and only went down to 102 on 2 extra strength Tylenol; extreme chills; shaking; nausea  for about 2 hours; I begin to get tired.; have A headache; sore arm at the injection site; no appetite  through the whole 2nd day; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had reported shellfish and gluten allergy. Concomitant medications included lamotrigine 150 (M4ANUFACTURER UNKNOWN), lithium 150 (MANUFACTURER UNKNOWN) and famotidine 20 (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in the left arm on 05Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 26Mar2021 at 14:15 (7 hours after vaccine), the patient experienced tired, headache (severe headache), sore arm, extreme chills and shaking (for about 8 hours) and nausea (for about 2 hours). At 20:15 (around 12 hours), the patient had fever went up to 103.5 (unspecified unit) (fever for about 8 hours), and only went down to 102. The through whole second day (27Mar2021), after fever broke the patient was tired and had a mild headache and no appetite. On 28Mar2021 (48 hours after vaccination), the patient awoke with pain and swelling in her armpit, but hungry. The patient still has arm soreness at the injection site. The pain and swelling in her armpit were very uncomfortable. The patient still tired but other than the arm, armpit and tiredness, was ok. Therapeutic measure was taken as result of event fever and included the treatment with 2 extra strengths of paracetamol (TYLENOL) and the fever went down to 102 (unspecified unit), for other events no treatment was given. The clinical outcome of event nausea was resolved on 26Mar2021 at 17:00 (for about 2 hours) and for events chills and shaking were resolved on 26Mar2021 at 23:00 (for about 8 hours); whereas for events tiredness, headache, vaccination site pain, fever, decreased appetite, armpit pain and hunger were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: pain and swelling in myarmpit; hungry; developed fever, went up to 103.5, and only went down to 102 on 2 extra strength Tylenol; extreme chills; shaking; nausea  for about 2 hours; I begin to get tired.; have A headache; sore arm at the injection site; no appetite  through the whole 2nd day; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had reported shellfish and gluten allergy. Concomitant medications included lamotrigine 150 (M4ANUFACTURER UNKNOWN), lithium 150 (MANUFACTURER UNKNOWN) and famotidine 20 (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in the left arm on 05Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 26Mar2021 at 14:15 (7 hours after vaccine), the patient experienced tired, headache (severe headache), sore arm, extreme chills and shaking (for about 8 hours) and nausea (for about 2 hours). At 20:15 (around 12 hours), the patient had fever went up to 103.5 (unspecified unit) (fever for about 8 hours), and only went down to 102. The through whole second day (27Mar2021), after fever broke the patient was tired and had a mild headache and no appetite. On 28Mar2021 (48 hours after vaccination), the patient awoke with pain and swelling in her armpit, but hungry. The patient still has arm soreness at the injection site. The pain and swelling in her armpit were very uncomfortable. The patient still tired but other than the arm, armpit and tiredness, was ok. Therapeutic measure was taken as result of event fever and included the treatment with 2 extra strengths of paracetamol (TYLENOL) and the fever went down to 102 (unspecified unit), for other events no treatment was given. The clinical outcome of event nausea was resolved on 26Mar2021 at 17:00 (for about 2 hours) and for events chills and shaking were resolved on 26Mar2021 at 23:00 (for about 8 hours); whereas for events tiredness, headache, vaccination site pain, fever, decreased appetite, armpit pain and hunger were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Axillary pain, Chills, Decreased appetite, Fatigue, Headache
Clinical narrative: pain and swelling in myarmpit; hungry; developed fever, went up to 103.5, and only went down to 102 on 2 extra strength Tylenol; extreme chills; shaking; nausea  for about 2 hours; I begin to get tired.; have A headache; sore arm at the injection site; no appetite  through the whole 2nd day; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had reported shellfish and gluten allergy. Concomitant medications included lamotrigine 150 (M4ANUFACTURER UNKNOWN), lithium 150 (MANUFACTURER UNKNOWN) and famotidine 20 (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in the left arm on 05Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 26Mar2021 at 14:15 (7 hours after vaccine), the patient experienced tired, headache (severe headache), sore arm, extreme chills and shaking (for about 8 hours) and nausea (for about 2 hours). At 20:15 (around 12 hours), the patient had fever went up to 103.5 (unspecified unit) (fever for about 8 hours), and only went down to 102. The through whole second day (27Mar2021), after fever broke the patient was tired and had a mild headache and no appetite. On 28Mar2021 (48 hours after vaccination), the patient awoke with pain and swelling in her armpit, but hungry. The patient still has arm soreness at the injection site. The pain and swelling in her armpit were very uncomfortable. The patient still tired but other than the arm, armpit and tiredness, was ok. Therapeutic measure was taken as result of event fever and included the treatment with 2 extra strengths of paracetamol (TYLENOL) and the fever went down to 102 (unspecified unit), for other events no treatment was given. The clinical outcome of event nausea was resolved on 26Mar2021 at 17:00 (for about 2 hours) and for events chills and shaking were resolved on 26Mar2021 at 23:00 (for about 8 hours); whereas for events tiredness, headache, vaccination site pain, fever, decreased appetite, armpit pain and hunger were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hunger, Nausea, Pain in extremity, Pyrexia, Tremor
Clinical narrative: pain and swelling in myarmpit; hungry; developed fever, went up to 103.5, and only went down to 102 on 2 extra strength Tylenol; extreme chills; shaking; nausea  for about 2 hours; I begin to get tired.; have A headache; sore arm at the injection site; no appetite  through the whole 2nd day; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had reported shellfish and gluten allergy. Concomitant medications included lamotrigine 150 (M4ANUFACTURER UNKNOWN), lithium 150 (MANUFACTURER UNKNOWN) and famotidine 20 (MANUFACTURER UNKNOWN) for unknown indications from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6203) via an unspecified route of administration in the left arm on 05Mar2021 at 08:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccines within four weeks prior to the COVID-19 vaccine. On 26Mar2021 at 14:15 (7 hours after vaccine), the patient experienced tired, headache (severe headache), sore arm, extreme chills and shaking (for about 8 hours) and nausea (for about 2 hours). At 20:15 (around 12 hours), the patient had fever went up to 103.5 (unspecified unit) (fever for about 8 hours), and only went down to 102. The through whole second day (27Mar2021), after fever broke the patient was tired and had a mild headache and no appetite. On 28Mar2021 (48 hours after vaccination), the patient awoke with pain and swelling in her armpit, but hungry. The patient still has arm soreness at the injection site. The pain and swelling in her armpit were very uncomfortable. The patient still tired but other than the arm, armpit and tiredness, was ok. Therapeutic measure was taken as result of event fever and included the treatment with 2 extra strengths of paracetamol (TYLENOL) and the fever went down to 102 (unspecified unit), for other events no treatment was given. The clinical outcome of event nausea was resolved on 26Mar2021 at 17:00 (for about 2 hours) and for events chills and shaking were resolved on 26Mar2021 at 23:00 (for about 8 hours); whereas for events tiredness, headache, vaccination site pain, fever, decreased appetite, armpit pain and hunger were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Fatigue, Feeling abnormal, Influenza like illness, Pain
Clinical narrative: face burned; looked like I had a sunburn; arm were bright red (especially around elbows); back itched; my face felt hot all day; flu like symptoms; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in right arm on 23Mar2021 at 14:45 (at the age of 69-years-old) as s single dose for COVID-19 immunisation. Medical history included allergic to cherries, apricots and sometimes allergic to sulphites. It was reported that the patient was healthy. Concomitant medications included vitamin b (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN), vitamin d (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indication and from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via an unspecified route of administration on an unknown date as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was not tested for COVID-19. The patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 24Mar2021 the patient experienced flu like symptoms and felt fine on 25Mar2021 and 26Mar2021. On 27Mar2021 the patient experienced burning sensation in face that looked like a sunburn, redness in arm (especially around elbows),itchy in back for few minutes, redness subsided in around half an hour but face felt hot all day. She never had anything like this before. The patient had not received treatments for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events flu like symptoms, burning sensation in face, sunburn, itchy in back and face felt hot were recovered on an unknown date in Mar2021, while that of redness in arm was recovered on 27Mar2021 at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Skin burning sensation
Clinical narrative: face burned; looked like I had a sunburn; arm were bright red (especially around elbows); back itched; my face felt hot all day; flu like symptoms; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in right arm on 23Mar2021 at 14:45 (at the age of 69-years-old) as s single dose for COVID-19 immunisation. Medical history included allergic to cherries, apricots and sometimes allergic to sulphites. It was reported that the patient was healthy. Concomitant medications included vitamin b (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN), vitamin d (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indication and from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via an unspecified route of administration on an unknown date as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was not tested for COVID-19. The patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 24Mar2021 the patient experienced flu like symptoms and felt fine on 25Mar2021 and 26Mar2021. On 27Mar2021 the patient experienced burning sensation in face that looked like a sunburn, redness in arm (especially around elbows),itchy in back for few minutes, redness subsided in around half an hour but face felt hot all day. She never had anything like this before. The patient had not received treatments for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events flu like symptoms, burning sensation in face, sunburn, itchy in back and face felt hot were recovered on an unknown date in Mar2021, while that of redness in arm was recovered on 27Mar2021 at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Erythema, Feeling hot, Influenza like illness, Pruritus
Clinical narrative: face burned; looked like I had a sunburn; arm were bright red (especially around elbows); back itched; my face felt hot all day; flu like symptoms; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in right arm on 23Mar2021 at 14:45 (at the age of 69-years-old) as s single dose for COVID-19 immunisation. Medical history included allergic to cherries, apricots and sometimes allergic to sulphites. It was reported that the patient was healthy. Concomitant medications included vitamin b (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN), vitamin d (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indication and from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via an unspecified route of administration on an unknown date as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was not tested for COVID-19. The patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 24Mar2021 the patient experienced flu like symptoms and felt fine on 25Mar2021 and 26Mar2021. On 27Mar2021 the patient experienced burning sensation in face that looked like a sunburn, redness in arm (especially around elbows),itchy in back for few minutes, redness subsided in around half an hour but face felt hot all day. She never had anything like this before. The patient had not received treatments for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events flu like symptoms, burning sensation in face, sunburn, itchy in back and face felt hot were recovered on an unknown date in Mar2021, while that of redness in arm was recovered on 27Mar2021 at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 69.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Sunburn
Clinical narrative: face burned; looked like I had a sunburn; arm were bright red (especially around elbows); back itched; my face felt hot all day; flu like symptoms; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in right arm on 23Mar2021 at 14:45 (at the age of 69-years-old) as s single dose for COVID-19 immunisation. Medical history included allergic to cherries, apricots and sometimes allergic to sulphites. It was reported that the patient was healthy. Concomitant medications included vitamin b (MANUFACTURER UNKNOWN), vitamin c (MANUFACTURER UNKNOWN), vitamin d (MANUFACTURER UNKNOWN) and melatonin (MANUFACTURER UNKNOWN), all for unknown indication and from unknown dates. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via an unspecified route of administration on an unknown date as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination the patient was not tested for COVID-19. The patient did not received any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 24Mar2021 the patient experienced flu like symptoms and felt fine on 25Mar2021 and 26Mar2021. On 27Mar2021 the patient experienced burning sensation in face that looked like a sunburn, redness in arm (especially around elbows),itchy in back for few minutes, redness subsided in around half an hour but face felt hot all day. She never had anything like this before. The patient had not received treatments for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the events flu like symptoms, burning sensation in face, sunburn, itchy in back and face felt hot were recovered on an unknown date in Mar2021, while that of redness in arm was recovered on 27Mar2021 at the time of this report.   No follow-up attempts are needed. No further information expected.
Age: 29.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Contusion, Oral blood blister, Petechiae
Clinical narrative: Petechiae on feet and ankles; bruising on feet and ankles; large blood blister inside mouth cheek; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733); via an unspecified route of administration in left arm on 23Mar2021 at 17:00 (at the age 29-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 24Mar2021 at 12:00, the patient experienced petechiae, bruising on feet and ankles and large blood blister inside mouth cheek. The patient underwent COVID-19 virus test (as reported pixel COVID test), via nasal swab on 26Mar2021 post vaccination and the result was negative. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of petechiae, bruising and blood blister was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Contusion, Full blood count abnormal, Petechiae, Platelet count decreased
Clinical narrative: Petechiae on feet and ankles; bruising on feet and ankles; large blood blister inside mouth cheek; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733); via an unspecified route of administration in left arm on 23Mar2021 at 17:00 (at the age 29-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 24Mar2021 at 12:00, the patient experienced petechiae, bruising on feet and ankles and large blood blister inside mouth cheek. The patient underwent COVID-19 virus test (as reported pixel COVID test), via nasal swab on 26Mar2021 post vaccination and the result was negative. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of petechiae, bruising and blood blister was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood blister, Contusion, Petechiae, SARS-CoV-2 test
Clinical narrative: Petechiae on feet and ankles; bruising on feet and ankles; large blood blister inside mouth cheek; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733); via an unspecified route of administration in left arm on 23Mar2021 at 17:00 (at the age 29-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history and concomitant medications. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 24Mar2021 at 12:00, the patient experienced petechiae, bruising on feet and ankles and large blood blister inside mouth cheek. The patient underwent COVID-19 virus test (as reported pixel COVID test), via nasal swab on 26Mar2021 post vaccination and the result was negative. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of petechiae, bruising and blood blister was not resolved at the time of reporting. No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate increased, Hypertension, Paraesthesia, Pharyngeal swelling, Swollen tongue
Clinical narrative: Swollen  tongue; itchy tongue; itchy tongue and throat; high blood pressure; very fast heartbeat; This is a spontaneous report received from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 10:15 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Patient had allergy with shellfish. The patient received rosuvastatin calcium (CRESTOR) within two weeks of vaccination from unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on unknown date as a single dose for COVID-19 immunisation. The patient not received any other vaccines within 4 weeks of vaccination. Prior to vaccination, the patient not had diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 10:30, the patient experienced swollen tongue, itchy tongue, throat itching, high blood pressure and very fast heartbeat. The patient did not receive any treatment for the events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events was recovered with sequelae.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate increased, Hypertension, Swollen tongue, Throat irritation, Tongue pruritus
Clinical narrative: Swollen  tongue; itchy tongue; itchy tongue and throat; high blood pressure; very fast heartbeat; This is a spontaneous report received from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received her second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Mar2021 at 10:15 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Patient had allergy with shellfish. The patient received rosuvastatin calcium (CRESTOR) within two weeks of vaccination from unknown date for unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on unknown date as a single dose for COVID-19 immunisation. The patient not received any other vaccines within 4 weeks of vaccination. Prior to vaccination, the patient not had diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 10:30, the patient experienced swollen tongue, itchy tongue, throat itching, high blood pressure and very fast heartbeat. The patient did not receive any treatment for the events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events was recovered with sequelae.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 76.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urticaria
Clinical narrative: Severe hives; This is a spontaneous report received from a contactable consumer, the patient. A 76-years old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the right arm on 26Jan2021 at 08:00 (at the age of 76-years old) as a single dose for COVID-19 immunisation. Patient medical history was not reported. The patient had no known allergies. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Jan2021 at 13:00, the patient experienced severe hives since day of vaccine. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event severe hives was unknown at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Hyperhidrosis, Pyrexia
Clinical narrative: Fever; General achiness; Chills; Heavy night sweats; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient was on a regimen of Keytruda immunotherapy for bladder cancer. The patient received other medications (unspecified) within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206), via an unspecified route of administration in the left arm on 03Mar2021 at 14:00 (at the age of 66-years-old), as a single dose for COVID-19 immunisation. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 09:00, the patient had experienced fever and general achiness starting on the second day following the vaccination. Fever has persisted between 100.8F - 102.2F during this time. Also, he had experienced chills, heavy night sweats and loss of appetite. Therapeutic measures included Tylenol 650 mg for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, generalised aching, chills, night sweats and appetite lost was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature, Chills, Decreased appetite, Night sweats, Pain
Clinical narrative: Fever; General achiness; Chills; Heavy night sweats; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient was on a regimen of Keytruda immunotherapy for bladder cancer. The patient received other medications (unspecified) within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206), via an unspecified route of administration in the left arm on 03Mar2021 at 14:00 (at the age of 66-years-old), as a single dose for COVID-19 immunisation. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 09:00, the patient had experienced fever and general achiness starting on the second day following the vaccination. Fever has persisted between 100.8F - 102.2F during this time. Also, he had experienced chills, heavy night sweats and loss of appetite. Therapeutic measures included Tylenol 650 mg for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, generalised aching, chills, night sweats and appetite lost was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; General achiness; Chills; Heavy night sweats; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient was on a regimen of Keytruda immunotherapy for bladder cancer. The patient received other medications (unspecified) within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206), via an unspecified route of administration in the left arm on 03Mar2021 at 14:00 (at the age of 66-years-old), as a single dose for COVID-19 immunisation. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 09:00, the patient had experienced fever and general achiness starting on the second day following the vaccination. Fever has persisted between 100.8F - 102.2F during this time. Also, he had experienced chills, heavy night sweats and loss of appetite. Therapeutic measures included Tylenol 650 mg for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, generalised aching, chills, night sweats and appetite lost was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Increased appetite, Pyrexia
Clinical narrative: Fever; General achiness; Chills; Heavy night sweats; loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613), via an unspecified route of administration in the left arm on 24Mar2021 at 13:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included bladder cancer. The patient was on a regimen of Keytruda immunotherapy for bladder cancer. The patient received other medications (unspecified) within 2 weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6206), via an unspecified route of administration in the left arm on 03Mar2021 at 14:00 (at the age of 66-years-old), as a single dose for COVID-19 immunisation. The patient did not have allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 09:00, the patient had experienced fever and general achiness starting on the second day following the vaccination. Fever has persisted between 100.8F - 102.2F during this time. Also, he had experienced chills, heavy night sweats and loss of appetite. Therapeutic measures included Tylenol 650 mg for the reported events. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever, generalised aching, chills, night sweats and appetite lost was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Injection site swelling, Pruritus
Clinical narrative: redness, itching, swelling lasting for two days around injection site 8 days after vaccine; redness, itching, swelling lasting fortwo days around injection site 8 daysafter vaccine; redness, itching, swelling lasting fortwo days around injection site 8 daysafter vaccine; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, Lot Number: EN6206) via unspecified route of administration in the right arm on 09Mar2021 at 14:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The medical history included rheumatoid arthritis. The patient was allergic to penicillin and clindamycin. The concomitant medication included adalimumab (HUMIRA). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 17Mar2021, 8 days after vaccine, the patient experienced redness (vaccination site erythema), itching (vaccination site pruritis) and swelling (vaccination site swelling) that had lasted for two days around the injection site. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the adverse events. The clinical outcome of redness, itching and swelling were recovered on 19Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: redness, itching, swelling lasting for two days around injection site 8 days after vaccine; redness, itching, swelling lasting fortwo days around injection site 8 daysafter vaccine; redness, itching, swelling lasting fortwo days around injection site 8 daysafter vaccine; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA vaccine, Lot Number: EN6206) via unspecified route of administration in the right arm on 09Mar2021 at 14:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. The medical history included rheumatoid arthritis. The patient was allergic to penicillin and clindamycin. The concomitant medication included adalimumab (HUMIRA). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient didn't receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 17Mar2021, 8 days after vaccine, the patient experienced redness (vaccination site erythema), itching (vaccination site pruritis) and swelling (vaccination site swelling) that had lasted for two days around the injection site. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the adverse events. The clinical outcome of redness, itching and swelling were recovered on 19Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Fatigue, Headache, Mood swings, Nausea
Clinical narrative: Headache; back pain; nausea; fatigue; This is a spontaneous report received from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 26Mar2021 at 11:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history included over weight (Body mass index (BMI-30)). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not have any allergies to food, medications, or other products. On 26Mar2021 at 15:00, the patient experienced headache, back pain, nausea and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. On an unspecified date the patients BMI included 30 kg/m2. The clinical outcome of the events headache, back pain, nausea and fatigue were recovering at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Body mass index, Fatigue, Headache, Nausea
Clinical narrative: Headache; back pain; nausea; fatigue; This is a spontaneous report received from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 26Mar2021 at 11:00 (at the age of 40-years-old), as a single dose for COVID-19 immunisation. Medical history included over weight (Body mass index (BMI-30)). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not have any allergies to food, medications, or other products. On 26Mar2021 at 15:00, the patient experienced headache, back pain, nausea and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. On an unspecified date the patients BMI included 30 kg/m2. The clinical outcome of the events headache, back pain, nausea and fatigue were recovering at the time of the report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Malaise, Throat tightness, Urticaria
Clinical narrative: approximately 52 hours after Injectionit felt like throat was tightening/closingup; Hives; overall feeling unwell; body aches; chills; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EL9262), via an unspecified route of administration in the left arm on 10Mar2021 at 14:30 (at the age of 25-years-old), as a single dose for COVID-19 immunisation. Medical history included CAH (congenital adrenal hyperplasia), asthma, steroid dependent, adrenal insufficiency, shellfish allergy and allergy to sulpha medications. Concomitant medications included hydrocortisone (CORTEF), montelukast sodium (SINGULAIR), levothyroxine sodium (SYNTHROID), metformin (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA); all for unspecified indications from unknown date. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient had not been tested for COVID-19, since the vaccination. On 10Mar2021 at 15:15, the patient experienced hives within 45 minutes, overall feeling unwell, body aches, chills and on 12Mar2021, approximately 52 hours after injection, the patient felt like throat was tightening/closing up. The adverse events result in a visit to the doctors or other healthcare professional office/clinic visit. The patient did not receive treatment for the reported events. The clinical outcome of hives, overall feeling unwell, body aches, chills, throat tightening/closing up was recovered on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information is expected.